- Home
- SGN vs QNRX Comparison
SGN vs QNRX Comparison
Compare SGN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- QNRX
- Stock Information
- Founded
- SGN 2019
- QNRX 2018
- Country
- SGN United States
- QNRX United States
- Employees
- SGN N/A
- QNRX N/A
- Industry
- SGN
- QNRX Medical/Dental Instruments
- Sector
- SGN
- QNRX Health Care
- Exchange
- SGN Nasdaq
- QNRX Nasdaq
- Market Cap
- SGN 3.8M
- QNRX 3.3M
- IPO Year
- SGN 2023
- QNRX N/A
- Fundamental
- Price
- SGN $1.08
- QNRX $9.60
- Analyst Decision
- SGN
- QNRX
- Analyst Count
- SGN 0
- QNRX 0
- Target Price
- SGN N/A
- QNRX N/A
- AVG Volume (30 Days)
- SGN 1.3M
- QNRX 12.9K
- Earning Date
- SGN 08-18-2025
- QNRX 08-07-2025
- Dividend Yield
- SGN N/A
- QNRX N/A
- EPS Growth
- SGN N/A
- QNRX N/A
- EPS
- SGN N/A
- QNRX N/A
- Revenue
- SGN $529,282.00
- QNRX N/A
- Revenue This Year
- SGN N/A
- QNRX N/A
- Revenue Next Year
- SGN N/A
- QNRX N/A
- P/E Ratio
- SGN N/A
- QNRX N/A
- Revenue Growth
- SGN 8.42
- QNRX N/A
- 52 Week Low
- SGN $0.44
- QNRX $5.01
- 52 Week High
- SGN $36.70
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- SGN 52.82
- QNRX 64.78
- Support Level
- SGN $0.92
- QNRX $8.04
- Resistance Level
- SGN $1.35
- QNRX $8.58
- Average True Range (ATR)
- SGN 0.17
- QNRX 0.46
- MACD
- SGN -0.02
- QNRX 0.04
- Stochastic Oscillator
- SGN 46.94
- QNRX 98.57
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.